Brazil's Jui raises R$2M to push gut-health powder into physical retail
What's the deal? JuiDealroom has a profile for this one. Try Dealroom →, a Brazilian foodtech that makes a powdered green juice aimed at gut health, has raised R$2 million (about $386,000) from undisclosed angel investors. The startup, founded in 2023, will use the money to widen distribution and prepare its entry into physical retail.
What's the endgame? Jui sells a powdered green juice built around natural ingredients such as psyllium, inulin, chlorella, and turmeric, developed over two years and 65 formulation tests. Its portfolio now spans three flavours, with each tub priced at R$179.90.
By the numbers: Jui made R$3 million in revenue in 2025, selling mainly through its own e-commerce site, where 40% of customers reorder. It projects R$9 million this year and R$20 million in 2027.
Why now? Cofounder Felipe Alda, 29, is betting on a fibre-consumption trend already gaining ground abroad. "We believe the fibre trend, stronger outside the country, will reach us in the next two years and we want to be well positioned to ride that moment," he said (translated from Portuguese).
The company sees GLP-1 weight-loss drug users as a potential audience, since diet changes can affect digestion. According to McKinseyDealroom has a profile for this one. Try Dealroom → research, gut health already ranks among the top benefits sought by supplement buyers.
What's the money for? The raise is meant to fund cash flow and inventory as Jui expands beyond digital into marketplaces such as Amazon and Mercado LivreDealroom has a profile for this one. Try Dealroom →, and courts large retailers. "It's hard to make R$20 million on digital alone," Alda said. "The funding is important to have cash flow and stock to serve bigger buyers."
Jui was founded by Alda and childhood friend André Dalem, 29, both with prior startup experience, backed by R$250,000 of their own capital. New products are being tested internally, with launches planned for 2027.
The signal: Jui's angel round sits in the upper tier of deals of its size, and reflects growing investor appetite for functional-food startups tied to health trends such as fibre intake and GLP-1 use. The founders say the operation is profitable and haven't ruled out a future raise.
Image credit: Generated with Gemini
Read more: PEGN
